Johnson & Johnson reported strong fourth-quarter and full-year 2011 results, exceeding analyst expectations with adjusted earnings per share above consensus. The company provided positive guidance for 2012, anticipating operational sales growth of 4â€“5% and improved pre-tax operating margins, reflecting confidence in future performance. Management's optimistic tone and emphasis on robust pipelines and strategic investments suggest a positive short-term impact on the stock price.

[1]